Rheumatoid factors revisited in the age of biologic therapy

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rheumatoid factor (RF) is crucial for diagnosing and classifying rheumatoid arthritis (RA).
• Different RF isotypes (e.g., IgM-RF, IgA-RF) correlate with RA severity and treatment outcomes.
• RF's role in RA pathogenesis involves immune complex formation, impacting medication response.

Purpose of the Study:

• To review the evolving understanding of RF in the context of biologic therapies for RA.
• To highlight the need for personalized treatment strategies based on serological profiles.

Main Methods:

• Narrative review of existing literature on RF and biologic therapies in RA.
• Analysis of differential efficacy of biologics (rituximab, abatacept, tocilizumab) based on RF status.
• Exploration of TNF inhibitors (TNFi) with and without IgG1-Fc fragments in RF-positive RA.

Main Results:

• RF-positive patients generally show better responses to certain biologics.
• TNF inhibitors lacking IgG1-Fc (e.g., certolizumab pegol) may be advantageous in RF-positive RA by mitigating immune complex formation.
• Heterogeneity in past studies necessitates further prospective research.

Conclusions:

• RF status is a key factor in predicting response to biologic therapies in RA.
• Personalized medicine approaches considering serological profiles and immune mechanisms are essential for optimizing RA treatment.
• Further randomized studies are required to validate specific therapeutic strategies for RF-positive RA patients.